publication venue for
- Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank.. 11. 2025
- Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer.. 10. 2024
- CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract.. 7. 2022
- Cost of Care in Open Cystectomy Patients Across Time and Space: Does it matter?. 7. 2022
- Impact of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Population Based Analysis.. 7. 2022
- Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.. 3. 2017
- Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy.. 3. 2017
- Micropapillary Bladder Cancer: Insights from the National Cancer Database.. 2. 2016
- Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.. 2. 2016
- Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.. 2. 2016
- Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.. 2. 2016
- The Pros and Cons of "Machination of Medicine" in Genitourinary Oncology Practice.. 7. 2022
- Antibody-Drug Conjugates in Bladder Cancer. 2018